


Supplementary Figure S6



Supplementary Figure S6: Immune responses after nivolumab treatment. Four available sets of PBMCs pre- and post-nivolumab treatment were subjected to the FCM analysis. PD1 were not detectable after nivolumab treatment suggesting successful blockade of the PD-1 molecule (A). Nivolumab treatment drove CD4⁺ T cell differentiation (B). There were trends of decreased CD56⁺ NK cells and CD19⁺ B cells after nivolumab treatment (C). Left panels show representative flow plots and right panels show pooled data from eight time points from four patients. Ly, lymphocytes; **, p<0.01; *, p<0.05; ns, not significant